PDF herunterladen
Aktuelle Neurologie 2003; 30(1): 18-26
DOI: 10.1055/s-2003-37060
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Diagnostik und Therapie bei Morbus Wilson

Bericht über 38 Jahre Behandlung in einer SpezialambulanzDiagnosis and Treatment of Wilson's DiseaseExperience of 38 Years Therapy in a Spezialised Out-Patients ClinicB.  Kunath1 , Ulrike  Reuner1
  • 1Klinik und Poliklinik für Neurologie der Medizinischen Fakultät der TU Dresden
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
03. Februar 2003 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Der Morbus Wilson ist eine hereditäre autosomal-rezessive Erkrankung des Kupferstoffwechsels. Mehr als 200 verschiedene Mutationen am Genort, der die kupfertransportierende ATP-Pase 7B kodiert (13q14,3), verursachen die Erkrankung. Lebersymptomatik tritt meist während der ersten, neurologische und psychiatrische Symptomatik in der zweiten oder dritten Lebensdekade, selten später, auf. Genotyp-Phänotyp-Korrelationen sind wahrscheinlich. Die Diagnostik umfasst Laboratoriumsuntersuchungen (Kupfermetabolismus), Molekulargenetik und - wenn notwendig - die Leberbiopsie. Die Behandlung muss lebenslang fortgeführt werden, ohne Unterbrechung, selbst während der Schwangerschaft. Neben D-Penicillamin, das das Mittel der ersten Wahl für viele Jahre darstellte, werden Trientine, Zink und Tetrathiomolybdat mit gutem Erfolg eingesetzt. Therapieüberwachung (Kupferbilanz, Nebenwirkungen) - zumindest ein- oder zweimal jährlich - ist notwendig. Zerebrale MRT- und FDG-PET-Untersuchungen sind von praktischem Nutzen für die Überwachung der Langzeittherapie. Die kontinuierliche Betreuung von Wilson-Patienten (38, davon 10 asymptomatisch) in einer Spezialambulanz hat sich seit 1964 bewährt. 31 Patienten, konsequent mit D-Penicillamin behandelt, hatten kaum Nebenwirkungen. Selbst schwere neurologische Symptomatik besserte sich, einige Patienten wurden symptomfrei. Alle asymptomatischen Patienten blieben asymptomatisch. Trientine und Zink stellten bei D-Penicillamin-Unverträglichkeit eine effektive alternative Therapie dar. Wiederholt traten bei zwei Patientinnen Leberdekompensationen auf, bei einer wurde eine Lebertransplantation erforderlich. 19 Schwangerschaften konnten unbeeinträchtigt ausgetragen werden, fetale Schädigungen traten nicht auf (17 behandelt mit D-Penicillamin, 2 mit Trientine und Zink). Unterbrechung der Therapie führte zu einem tödlichen Leberversagen bei einer Schwangeren.

Abstract

Wilson's disease, an hereditary autosomal recessive disorder, is caused by more than 200 different mutations in the gene (locus 13q14,3), encodes a copper-transporting ATPase 7B. Hepatic manifestations became apparent mainly during the first, neurological and psychiatric during the second or third decade of life, seldom later. Genotype-phaenotype correlations are probably. The diagnosis involves laboratory tests (Cu-metabolism), molecular genetics and, if necessary, liver biopsy. Treatment must be continued lifelong, without disruption, also in the pregnancy. Besides D-Penicillamin, which has been the drug of choice for many years, Trientine, zinc and tetrathiomolybdate are used with good success. Monitoring (copper balance, side effects) - at least once or twice yearly - is necessary. Cerebral MRI and FDG-PET seems to be a useful tool in practise for long-term therapy. Continuous care of Wilson patients (38, 10 of among them without hepatic or neurological signs) in a specialised outpatients clinic since 1964 has proven worth. 31 patients consistently treated with D-Penicillamin tolerated the drug well with few side effects. Even marked neurological symptoms improved, some patients became virtually free of symptoms. All patients without clinical signs remained free of symptoms. If intolerance to D-Penicillamin occurs, Trientine and zinc are an effective alternative therapy. Recurrent hepatic decompensations were observed in 2 female patients. One of them eventually required a liver transplant. 19 pregnancies could be carried to full term without complications or fetal damage while taking medication (17 with D-Penicillamin, 2 with Trientine and zinc). Discontinuation of therapy resulted in fatal hepatic failure in one pregnant patient.

Literatur

  • 1 Walshe J M. Penicillamine, a new oral therapy for Wilson's disease.  Am J Med. 1956;  21 487-495
    CrossrefPubMedGoogle Scholar
  • 2 Bachmann H, Lössner J, Kühn H J, Siegemund R. Diagnostic strategies in Wilson's disease. In: Czlonkowska A, Van den Hamer CJA (eds) Proceedings of the 5th Symposium on Wilson's Disease. Delft; University Press 1991: 79-81
    Google Scholar
  • 3 Reilly M, Daly L, Hutchinson M. An epidemiological study of Wilson's disease in the Republic of Ireland.  J Neurol Psychiat. 1993;  56 298-300
    PubMedGoogle Scholar
  • 4 Olivarez L, Caggana M, Pass K A. et al . Estimate of the frequency of Wilson's disease in the US caucasians population: a mutation analysis approach.  Ann Hum Genet. 2001;  65 459-493
    CrossrefPubMedGoogle Scholar
  • 5 Schilsky M L. Wilson Disease: Genetic basis of copper toxity and natural history.  Semin Liver disease. 1996;  16 83-95
    PubMedGoogle Scholar
  • 6 Chowrimootoo G FE, Andoh J, Seymour C A. Isolation of coeruloplasmin binding protein in the human liver.  Z Gastroenterol. 2001;  39 238
    PubMedGoogle Scholar
  • 7 Chowrimootoo G FE, Scowcroft H, Seymour C A. Coeruloplasmin isoforms in Wilson's disease in neonates.  Arch Dis Child Fetal Neonatal Ed. 1998;  79 198-201
    PubMedGoogle Scholar
  • 8 Scheinberg I H, Sternlieb I. Wilson's disease and idiopathic copper toxicosis.  Am J Clin Nutr. 1996;  63 842-845
    PubMedGoogle Scholar
  • 9 Betard C, Rasquin-Weber A, Brewer C. et al . Localisation of a recessiv gene for North American Indian childhood cirrhosis to chromosome region 16q22-and identification of a shared haplotype.  Am J Hum Genet. 2000;  67 222-228
    CrossrefPubMedGoogle Scholar
  • 10 Bull P C, Thomas G R, Rommens J M. et al . The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene.  Nat Genet. 1993;  5 327-337
    CrossrefPubMedGoogle Scholar
  • 11 Tanzi R E, Petrukhin K, Chernow J. et al . The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene.  Nat Genet. 1993;  5 344-350
    CrossrefPubMedGoogle Scholar
  • 12 Chu N S, Hung T P. Geographic variations in Wilson's disease.  J Neurol Sci. 1993;  117 1-7
    CrossrefPubMedGoogle Scholar
  • 13 Caca K, Ferenci P, Kühn H-J. et al . High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype-genotype analysis.  J Hepatol. 2001;  35 575-581
    CrossrefPubMedGoogle Scholar
  • 14 Sommer G, Genschel J, Czlonkowska A. et al . Mutation analysis of the WD gene ATPase7B - Identification of novel mutations.  Z Gastroenterol. 2001;  39 244
    PubMedGoogle Scholar
  • 15 Waldmström E, Portala K, Westermark K. Phenotype and genotype in Swedish patients homozygous formations in Wilson disease gene.  Z Gastroenterol. 2001;  39 245
    PubMedGoogle Scholar
  • 16 Danks D M, Metz G, Sewell R, Prewett E J. Wilson's disease in adults with cirrhosis but no neurological abnormalities.  Brit Med J. 1990;  301 331-332
    PubMedGoogle Scholar
  • 17 Czlonkowska A, Rodo M. Late onset of Wilson's disease: report of a family.  Arch Neurol. 1981;  38 729-730
    PubMedGoogle Scholar
  • 18 Ross M E, Jacobson J M, Dienstag J L, Martin J B. Late onset Wilson's disease with neurological involvement in the absence of Kayser-Fleischer-rings.  Ann Neurol. 1985;  17 411-413
    CrossrefPubMedGoogle Scholar
  • 19 Kunath B. Zur Psychopathologie der hepatozerebralen Degeneration.  Fortschr Neurol Psychiat. 1969;  37 91-106
    PubMedGoogle Scholar
  • 20 Menerey K A, Eider W, Brewer G J. et al . The arthropathy of Wilson's disease Clinical and pathological features.  J Rheumatol. 1988;  15 331-337
    PubMedGoogle Scholar
  • 21 Smolarek C, Smolarek E, Stremmel W. Osteoporosis and osteopenia - neglected manifestations of wilson disease.  Z Gastroenterol. 2001;  39 248
    PubMedGoogle Scholar
  • 22 Mareckova Z, Marecek Z, Linkart A. et al . Cardiac involvement in Wilson's disease.  Z Gastroenterol. 2001;  39 247
    PubMedGoogle Scholar
  • 23 Kuan P. Cardiac Wilson's disease.  Chest. 1987;  91 579-583
    PubMedGoogle Scholar
  • 24 Yoshita K, Furihata K, Taketa S. et al . A mutation in the coeruloplasmin gene is associated with systemic hemosiderosis in humans.  Nat Genet. 1995;  9 268-272
    PubMedGoogle Scholar
  • 25 Biesold D, Kunath B. Hepatocerebrale Degeneration „Morbus Wilson” 1. Mitteilung.  Dtsch Gesundheitsw. 1969;  24 1121-1124
    PubMedGoogle Scholar
  • 26 Günther K, Biesold D, Lössner J, Löbe J. Zur Diagnostik der Kupferstoffwechselstörung bei Morbus Wilson.  Dtsch Gesundheitsw. 1973;  28 607-611
    PubMedGoogle Scholar
  • 27 Sternlieb I. Scheinberg IH. The role of radio copper in the diagnosis of Wilson's disease.  Gastroenterol. 1979;  77 138-142
    PubMedGoogle Scholar
  • 28 Starosta-Rubinstein S, Young A B, Kluin K, Hill G. et al . Clinical assessment of 31 patients with Wilson's disease. Correlations with structur changes on magnetic resonance imaging.  Arch Neurol. 1987;  44 365-370
    CrossrefPubMedGoogle Scholar
  • 29 van Wassenaer-van Hall H N, van den Heuvel A G, Jansen G H. et al . Cranial MR in Wilson disease: abnormal white matter in extrapyramidal and pyramidal tracts.  Am J Neuroradiol. 1995;  16 2021-2027
    PubMedGoogle Scholar
  • 30 Westermark K, Tedroff J, Thuomas K A. et al . Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomographic using dopaminergie markers.  Mov Disord. 1995;  10 596-603
    CrossrefPubMedGoogle Scholar
  • 31 Cordato D J, Fulham J, Yiannikas C. Pretreatment and posttreatment positron emission Tomographic Scan Imaging in a 20-year-old Patient with Wilson's disease.  Mov Disord. 1998;  13,1 162-166
    PubMedGoogle Scholar
  • 32 Kunath B, Reuner U, v Kummer R. et al . MRT, FDG-PET and neurophysiology in Wilson disease during therapy.  Z Gastroenterol. 2001;  39 243
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 33 Cumings J N. The effect of BAL in hepatolenticular degeneration.  Brain. 1951;  74 10-22
    PubMedGoogle Scholar
  • 34 Walshe J M. Wilson's disease (hepatolenticular degeneration). In: Vinken PJ, Bruyn GW, Klawans HJ Handbook of Clinical Neurology, Metabolic and Deficiency Diseases of Nervous System. New York; American Elsevier 1976 27, Part I: 379-414
    Google Scholar
  • 35 Trautmann B, Storch W. Zum Nachweis von Antikörpern gegen D-Penicillamin. 3 Mitteilung: Nachweis von Antikörpern gegen D-Penicillamin im Serum von Patienten mit Morbus Wilson unter Behandlung mit D-Penicillamin.  Pharmazie. 1986;  41 126-127
    PubMedGoogle Scholar
  • 36 Huang C C, Chû N S. Acute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in wilson's disease.  Eur Neurol. 1998;  39 32-37
    CrossrefPubMedGoogle Scholar
  • 37 Scheinberg I H, Sternlieb I. Wilson's Disease, Vol 23, Major Problems in Internal Medicine. Philadelphia; Saunders WB 1984
    Google Scholar
  • 38 Grasedyck K. D-Penicillamin-Nebenwirkungen, Pathogenese und Risikominderung.  Z Rheumatol. 1988;  47, Suppl 1 17-19
    PubMedGoogle Scholar
  • 39 Dixon H B, Gibbs K, Walshe J M. Preparation of triethylenetetramine dihydrochloride for the treatment of Wilson's disease.  Lancet. 1972;  1 853
    PubMedGoogle Scholar
  • 40 Siegemund R, Lössner J, Günther K. et al . Mode of action of triethylentetramin dihydrochloride on copper metabolism in Wilson's disease.  Acta Neurol Scand. 1991;  83 364-366
    PubMedGoogle Scholar
  • 41 Morita J, Yoshino M, Watari H. et al . Wilson's disease treatment by triethylenetetramine dihydrochloride (Trientine): long-term observations.  Dev Pharmacol Ther. 1992;  19 6-9
    PubMedGoogle Scholar
  • 42 Scheinberg I H, Jaffe M E, Sternlieb I. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease.  New Engl J Med. 1987;  317 209-213
    PubMedGoogle Scholar
  • 43 Hoogenraad T U, van den Hamer C J. 3 Years of continuous oral zinc therapy in 4 patients with Wilson's disease.  Acta Neurol Scand. 1983;  67 356-364
    PubMedGoogle Scholar
  • 44 Hoogenraad T U. Wilson's Disease. London; Saunders WB Company Ltd 1996
    Google Scholar
  • 45 Brewer G J, Dick R D, Johnson V D. et al . Treatment of Wilson's disease with zinc. XV Long-term follow up studies.  J Lab Clin Med. 1998;  132 264-278
    CrossrefPubMedGoogle Scholar
  • 46 Najda J, Stella-Holowiecka B, Machalski M. Low-dose zinc administration as an effective Wilson disease treatment.  Biol Trace Elem Res. 2001;  80 281-284
    CrossrefPubMedGoogle Scholar
  • 47 Anderson L A, Hakojarvi S L, Boudreaux S K. Zinc acetat treatment in Wilson's disease.  Ann Pharmacother. 1998;  32 78-87
    PubMedGoogle Scholar
  • 48 Walshe J M. Orphan drugs: food for thought. In: Scheinberg IH, Walshe JM (eds) Orphan Diseases and Orphan Drugs. Manchester; University Press 1986: 1-5
    Google Scholar
  • 49 Brewer G J, Dick R D, Johnson V. et al . Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients.  Arch Neurol. 1994;  51 545-554
    PubMedGoogle Scholar
  • 50 Brewer G J, Dick R D, Johnson V. et al . Treatment of Wilson's disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow up with zinc therapy.  Arch Neurol. 1996;  53 1017-1025
    PubMedGoogle Scholar
  • 51 Brewer G J. Tetrathiomolybdate for initial therapy of neurological Wilson disease.  Z Gastroenterol. 2001;  39 251
    PubMedGoogle Scholar
  • 52 Messner U, Gunter H H, Niesert S. Morbus Wilson und Schwangerschaft. Literaturübersicht und kasuistische Mitteilung.  Z Geburtshilfe Neonatal. 1998;  202 77-79
    PubMedGoogle Scholar
  • 53 Brewer G J, Johnson V D, Dick R D. et al . Treatment of Wilson's disease with zinc. VXVII: treatment during pregnancy.  Hepatology. 2000;  31 364-370
    CrossrefPubMedGoogle Scholar
  • 54 Carpenter T O, Carnes D L, Anast C S. Hypoparathyroidism in Wilson's disease.  New Engl J Med. 1983;  309 873-877
    PubMedGoogle Scholar
  • 55 Czlonkovska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson's disease with D-Penicillamin and zinc sulfate.  J Neurol. 1996;  243 269-273
    PubMedGoogle Scholar
  • 56 Walshe J M. Penicillamine: the treatment of first choise for patients with Wilson's disease.  Mov Disord. 1999;  14 545-550
    CrossrefPubMedGoogle Scholar
  • 57 Brewer G J. Penicillamin should not be used as initial therapy in Wilson's disease.  Mov Disord. 1989;  14 551-554
    PubMedGoogle Scholar
  • 58 Le Witt P A. Penicillamine as a controversial treatment for Wilson's disease.  Mov Disord. 1999;  14 553-556
    PubMedGoogle Scholar

Prof. Dr. Bernhard Kunath

Klinik und Poliklinik für Neurologie der Medizinischen Fakultät der TU Dresden

Fetscherstraße 74

01307 Dresden

      >